TRPV1: A Target for Rational Drug Design
AbstractTransient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca2+ permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). Many compounds have been developed that either activate or inhibit TRPV1, but none of them are in routine clinical practice. This review will discuss the rationale for antagonists and agonists of TRPV1 for pain relief and other conditions, and strategies to develop new, better drugs to target this ion channel, using the newly available high-resolution structures. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Carnevale, V.; Rohacs, T. TRPV1: A Target for Rational Drug Design. Pharmaceuticals 2016, 9, 52.
Carnevale V, Rohacs T. TRPV1: A Target for Rational Drug Design. Pharmaceuticals. 2016; 9(3):52.Chicago/Turabian Style
Carnevale, Vincenzo; Rohacs, Tibor. 2016. "TRPV1: A Target for Rational Drug Design." Pharmaceuticals 9, no. 3: 52.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.